226 related articles for article (PubMed ID: 32538280)
1. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
[TBL] [Abstract][Full Text] [Related]
2. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
[TBL] [Abstract][Full Text] [Related]
4. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
[TBL] [Abstract][Full Text] [Related]
5. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
[TBL] [Abstract][Full Text] [Related]
6. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
[TBL] [Abstract][Full Text] [Related]
7. Preclinical PET Studies of [
Thomsen MB; Schacht AC; Alstrup AKO; Jacobsen J; Lillethorup TP; Bærentzen SL; Noer O; Orlowski D; Elfving B; Müller HK; Brooks DJ; Landau AM
Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
[TBL] [Abstract][Full Text] [Related]
8. Potential of [
Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
[TBL] [Abstract][Full Text] [Related]
9. Imaging of Synaptic Density in Neurodegenerative Disorders.
Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ
J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of synaptic density with [
Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
[TBL] [Abstract][Full Text] [Related]
12. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
Bertoglio D; Halloin N; Lombaerde S; Jankovski A; Verhaeghe J; Nicaise C; Staelens S
J Nucl Med; 2022 Aug; 63(8):1245-1251. PubMed ID: 35027368
[TBL] [Abstract][Full Text] [Related]
13. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
[TBL] [Abstract][Full Text] [Related]
16. Validation and noninvasive kinetic modeling of [
Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
[TBL] [Abstract][Full Text] [Related]
17. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
[TBL] [Abstract][Full Text] [Related]
18. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain.
Varnäs K; Stepanov V; Halldin C
Synapse; 2020 Oct; 74(10):e22157. PubMed ID: 32259300
[TBL] [Abstract][Full Text] [Related]
19. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
Kumar A; Scarpa M; Nordberg A
Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
[TBL] [Abstract][Full Text] [Related]
20. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
